Stock Financial Ratios, Dividends, Split History

ASX:RMD / RESMED INC financial ratios include Market Cap, Enterprise Value, Book Value, Quick Ratio, Current Ratio, NCAV, EBITDA, Profit Margin, Operating Margin, Return on Invested Capital (ROIC), Return on Assets (ROA), Return on Equity (ROE), Piotroski F-Score, Altman Z-Score, Beneish M Score and Kaplan-Zingales KZ-Index.

Valuation Metrics
Market Cap ($M)0.00
Enterprise Value ($M)105.72
Book Value ($M)2,066.96
Book Value / Share14.48
Price / Bookn/a
NCAV ($M)137.16
NCAV / Share0.96
Price / NCAVn/a
Share Statistics
Weighted Average Number Of Diluted Shares Outstanding 142,453,000
Common Stock Shares Outstanding 142,174,724
Weighted Average Number Of Shares Outstanding Basic 141,360,000
Common Shares Outstanding 142,209,115
Weighted Average Number Diluted Shares Outstanding Adjustment 1,093,000
Scoring Models
Piotroski F-Score5.00
Altman Z ScoreN/A
Beneish M ScoreN/A
Management Effectiveness (mra)
Return on Invested Capital (ROIC)0.11
Return on Assets (ROA)0.11
Return on Equity (ROE)0.20
Balance Sheet (mrq) ($M)
Quick Ratio2.85
Current Ratio3.48
Income Statement (mra) ($M)
Sales Revenue Goods Net2,066,737,000.00
Operating Income425.80
Net Income342.28
Earnings Per Share Diluted2.40
Earnings Per Share Basic2.42
Cash Flow Statement (mra) ($M)
Cash From Operations414.05
Cash from Investing-81.89
Cash from Financing414.05
Identifiers and Descriptors
Central Index Key (CIK)943819

Split History

Stock splits are used by RESMED INC to keep share prices within reasonable numbers to encourage investment. If the share price of a security gets too high, a company can perform a stock split by issuing all shareholders an extra share, thereby halving the price of an individual share. If the share price gets too low, companies can do reverse splits. This is common when share prices drop below $1.00 and company's become in danger of being delisted. However, because of the cost, stock splits are not a normal business occurrence.

Coming soon

Related Articles

ARWR: Arrowhead Pharmaceuticals Analysis and Research Report

4h - Asif

Business Arrowhead develops medicines that treat intractable diseases by silencing the genes that cause them. Using a broad portfolio of RNA chemistries and efficient modes of delivery, Arrowhead therapies trigger the RNA interference mechanism to induce rapid, deep and durable knockdown of target genes. RNA interference, or RNAi, is a mechanism present in living cells that inhibits the expression of a specific gene, thereby affecting the production of a specific protein. Deemed to be one of the most important recent discoveries in life science with the potential to transform medicine, the discoverers of RNAi were awarded a Nobel Prize in 2006 for their work. Arrowhead’s RNAi-based therapeutics leverage this natural pathway of gene silencing. In fiscal 2017, Arrowhead refocused its resources on therapeutics that exclusively utilize the company’s Targeted RNAi Molecule (TRiMTM) platform technology. Therapeutics built on the TRiMTM platform have demonstrated high levels of pha...

PRTO: Proteon Therapeutics Analysis and Research Report

2018-06-11 - Asif

Overview Proteon Therapeutics is a late-stage biopharmaceutical company focused on the development of novel, first-in-class pharmaceuticals to address the needs of patients with renal and vascular disease. The company's product candidate, vonapanitase, is a recombinant human elastase that Proteon Therapeutics is developing to improve vascular access outcomes in patients with chronic kidney disease, or CKD, undergoing or planning for hemodialysis, a lifesaving treatment that cannot be conducted without a functioning vascular access. The company believe data from its completed Phase 2 and Phase 3 clinical trials of vonapanitase support that a one-time, local application of investigational vonapanitase during surgical creation of a radiocephalic fistula for hemodialysis may improve fistula use for hemodialysis and secondary patency (time to fistula abandonment), thereby improving patient outcomes and reducing the burden on patients and the healthcare system. Arteriovenous fistu...

GALE: Galena Biopharma Analysis and Research Report

2018-06-11 - Asif

Overview Galena Biopharma is a clinical-stage biopharmaceutical company focused on novel cancer immunotherapeutics for a broad range of cancer indications. The company's lead product candidate, galinpepimut-S, or GPS, is a cancer i unotherapeutic agent licensed from Memorial Sloan Kettering Cancer Center, or MSK, that targets the Wilms tumor 1, or WT1, protein, which is present in 20 or more cancer types. Based on its mechanism of action as a directly immunizing agent, GPS has the potential as a monotherapy or in combination with other immunotherapeutic agents to address a broad spectrum of hematologic, or blood, cancers and solid tumor indications. Phase 2 clinical trials for GPS have been completed and Galena Biopharma has planned Phase 3 clinical trials (pending funding availability) for two indications, acute myeloid leukemia, or AML, and malignant pleural mesothelioma, or MPM. GPS is also in development as a potential treatment for multiple myeloma, or MM, and ovarian can...

Related News Stories

ResMed Reports Positive Results for Bilevel PAP Device Study

2018-06-07 zacks
ResMed Inc. (RMD - Free Report) recently announced positive results from a company-sponsored research, supporting the efficiency of bilevel devices. The results were presented at SLEEP, an annual joint meeting of the American Academy of Sleep Medicine and the Sleep Research Society. (10-0)

The 10 Best Stocks to Buy for the Next Decade

2018-06-01 investorplace
Last year, InvestorPlace contributor Dan Burrows highlighted the 10 best-performing S&P 500 stocks of the past decade. The most important lesson one finds studying these high-flying stocks is that patience wins out over all other attributes of a successful investor. (332-0)

Illumina (ILMN) Grows on Innovation & Strategic Partnerships

2018-06-01 zacks
On May 30, we issued an updated research report on Illumina, Inc. (ILMN - Free Report) , a Zacks Rank #3 (Hold) stock. The company’s market opportunities continue to expand owing to accelerated demand from clinical and translational customers. Its recent strategic collaborations are also expected to widen its product portfolio. (23-0)

ResMed's (RMD) HEALTHCAREfirst Buyout to Boost SaaS Business

2018-05-30 zacks
ResMed, Inc. (RMD - Free Report) recently announced a definitive agreement to buy HEALTHCAREfirst— a privately-held provider of software solutions and services to home health and hospice agencies. After meeting certain customary closing conditions and receiving regulatory approvals, the deal is expected to be finalized before the end of first-quarter fiscal 2019 (per ResMed’s calendar). (38-0)

Top Ranked Momentum Stocks to Buy for May 29th

2018-05-29 zacks
Here are four stocks with buy rank and strong momentum characteristics for investors to consider today, May 29th: (7-0)